Ongoing Prospective Trials Evaluating Impact of PET/CT on Prostate Cancer Treatment
| Trial no. | PET probe | Cohort | Phase | Arms | Patients (n) | Primary endpoint | Sponsor |
| NCT02578940 | 18F-fluciclovine | Biochemical failure after local therapy | 3 | Single arm: 18F-fluciclovine PET | 180 | Impact on SRT | Blue Earth Diagnostics |
| NCT01804231 | 18F-fluorocholine | Biochemical failure after local therapy and negative conventional imaging | 2 | Single arm: 18F-FCH PET/MRI | 22 | Impact on SRT | Lawson Health Research Institute |
| NCT02131649 | 18F-fluorocholine | Biochemical failure after surgery and negative conventional imaging | 2 | Single arm: 18F-FCH PET/CT, planned for SRT | 140 | Impact on SRT | Lawson Health Research Institute |
| NCT01804231 | 18F-fluorocholine | Biochemical failure after local therapy and negative conventional imaging | 2 | Single arm: 18F-FCH PET/MRI | 22 | Impact on SRT | Lawson Health Research Institute |
| NCT03160794 | 18F-DCFPyL | Biochemical failure after surgery and negative conventional imaging | 2 | Single arm: 18F-DCFPyL PET/MRI | 75 | Detection of oligorecurrent disease, biochemical response to oligometastatic SBRT | University of Toronto |
| NCT02131649 | 18F-fluorocholine | Biochemical failure after surgery and negative conventional imaging | 2 | Single arm: 18F-FCH PET/MRI | 140 | Evidence of extraprostatic disease on PET | Lawson Health Research Institute |
| NCT03232164 | 18F-DCFPyL | Presurgery, pre-SRT, or metastatic | 1 | Single arm: 18F-DCFPyL PET/MRI | 36 | Biochemical response for pre-SRT patients | University of Wisconsin |
| NCT02976402 | Any PSMA or 11C-choline | Biochemical failure after surgery and no distant metastases by PSMA or 11C-choline PET | 1 | Single arm: any PSMA or 11C-choline PET/CT | 30 | Feasibility of delivering SRT by SBRT technique | Fundacao Champalimaud |
| NCT02004418 | 11C-choline | Intermediate-risk localized prostate cancer | 2 | Single arm: 11C-choline PET–guided prostate radiotherapy with simultaneous integrated boost | 63 | 3- and 5-y failure-free survival, toxicity | AHS Cancer Control Alberta |
| NCT01558427 | 11C-choline | Oligometastatic recurrence after local therapy | 2 | Arm A: observation; arm B: 11C-choline PET–guided metastasis-directed therapy (including SBRT) | 54 | Time to initiation of androgen deprivation | University Hospital, Ghent |
| NCT01666808 | 18F-fluciclovine | Biochemical failure after surgery and negative conventional imaging | 3 | Arm A: 18F-fluciclovine PET–guided SRT; arm B: routine SRT | 162 | 3-y failure-free survival | Emory University |
| NCT03253744 | 18F-DCFPyL | Biochemical failure after definitive radiation | 1 | Single arm: salvage SBRT guided by PET/CT | 52 | Safety/maximum tolerated dose | National Cancer Institute |